Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 24 Mar 2015 Protocol has been amended to change in incl/excl criteria, treatment arms, primary endpoint and patient number.
- 24 Mar 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 04 Jun 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.